Spread the love
  •  
  •  
  •  
  •  

AP Photo/Alex Brandon Gilead Science has announced the pricing of remdesivir to treat the typical COVID-19 patient. Honestly, $3,210 is not bad for a drug that was developed years ago that didn’t work for the intended disease. Drug development is expensive, and those costs need to be recovered. The price will become effective in July after the manufacturer donated the treatment through May and June.

There will be a two-tiered pricing system in the United States with patients who are commercially insured paying more. How much more isn’t clear, but for those on Medicare, the cost will be $390 per dose. The pitch is that this will reduce the number of days a patient is in the hospital by an average of four. Gilead Chief Executive Daniel O’Day estimates an average of $12,000 in length-of-stay savings. Remdesivir

According to the NIH , remdesivir shows statistically significant improvement for those requiring supplemental oxygen in days to recovery. According to the clinical trial, it does not improve mortality rates in a significant way. Stated differently, people who were going to get better, get better faster. Those who were not will still die.

So while it can improve recovery time, it does not do what we would hope. It does not save lives. However, doctors and researchers are providing what could be lifesaving treatments that are not getting nearly enough attention. Cytokine Storms

The Wall Street Journal and several clinicians have reported that a significant number of patients who contract COVID-19 become severely ill with a condition called a cytokine storm. This syndrome is an overreaction of a patient’s immune system that can mimic an autoimmune disorder.

An autoimmune disorder causes a person’s immune system to attack other body tissues. This process would explain the full range of symptoms described in severe COVID-19 as well […]


Spread the love
  •  
  •  
  •  
  •